The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3108-3116

  Clark, D E ^a,b   Errington, T M ^a,b   Smith, J A ^b   Frierson Jr , H F ^b   Weber, M J ^a   Lannigan, D A ^a,b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P300; PROTEIN P90; PROTEIN SERINE THREONINE KINASE; S6 KINASE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE;

EID: 17144376084     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3151     Document Type: Article

References (46)

1. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-90.
2. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-16.
3. Chang C, Saltzman A, Yeh S, et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 1995;5:97-125.
4. Heinlein CA, Chang, C Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
5. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
6. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-9.
7. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
8. Bakin KE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003;63:1975-80.
9. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
10. Nebreda AR, Gavin AC. Perspectives: signal transduction. Cell survival demands some Rsk. Science 1999;286:1309-10.
11. Yntema HG, van den Helm B, Kissing J, van Duijnhoven G, et al. A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in patients with complex X-linked mental retardation. Genomics 1999;62:332-43.
12. Berns K, Hijmans EM, Mullenders J, et al. large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004;428:431-7.
13. Myers AP, Corson LB, Rossant J, Baker JC. Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol 2004;24:4255-66.
14. Dummler BA, Hauge C, Silber J, et al. Functional characterization of RSK4, a new 90 kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem 2005. Epub ahead of print.
15. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse bioiogical functions. Microbiol Mol Biol Rev 2004;68:320-44.
16. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 2004;101:13489-94.
17. Yang X, Matsuda K, Bialek P, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 2004;117:387-98.
18. Woo MS, Ohta Y, Rabinovitz I, Stossel TP, Blenis J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol 2004;24:3025-35.
19. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998;18:1978-84.
20. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA. Rsk2 allosterically activates estrogen receptor α by docking to the hormone-binding domain. EMBO J 2001;20:3484-94.
21. Joel PB, Traish AM, Lannigan DA. Estradiol-induced phosphorylation of Serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 1998;273:13317-23.
22. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. In Press; 65.
23. Poteet-Smith CE, Smith JA, Lannigan DA, Freed TA, Sturgill TW. Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activaied protein kinase family. J Biol Chem 1999;274:22135-38.
24. Fernandez PL, Hernandez L, Farre X Campo E, Cardesa A. Alterations of cell cycle-regulatory genes in prostate cancer. Pathobiology 2002;70:1-10.
25. Nakajima T, Fukamizu A, Takahashi J, et al. The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Cell 1996;86:465-74.
26. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 1995;9:208-18.
27. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. Expression of ERα and ERβ in prostate cancer. Prostate 2003;55:180-6.
28. Maggiolini M, Recchia AG, Carpino A, et al. Oestrogen receptor β is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 2004;32:777-91.
29. Leighton IA, Dalby KN, Caudwell FB, Cohen PT, Cohen P. Comparison of the specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 S6 kinase: the N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation. FEBS Lett 1995; 375:289-93.
30. Poujol N, Wurtz JM, Tahiri B, et al. Specific recognition of androgens by their nuclear receptor. A structure-function study. J Biol Chem 2000;275: 24022-31.
31. Matias PM, Donner P, Coelho R, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000;275: 26164-71.
32. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63: 7638-40.
33. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62: 5632-6.
34. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17: 16-23.
35. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
36. Frodin M, Jensen CJ, Merienne K, Gammeltoft S. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J 2000;19:2924-34.
37. Smith JA, Poteet-Smith CE, Malarkey K, Sturgill TW. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J Biol Chem 1999; 274:2893-8.
38. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnositics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98: 10031-3.
39. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98: 103144-9.
40. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996; 399:333-8.
41. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 2001;98:7200-5.
42. Gioeli D, Ficarro SB, Kwiek JJ, et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277: 29304-14.
43. Merienne K, Pannetier S, Harel-Bellan A, Sassone-Corsi P. Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities. Mol Cell Biol 2001;21:7089-96.
44. Fu M, Wang C, Reutens AT, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000;275:20853-60.
45. Tukey JW. Box-and-Whisker Plots. In: Tukey JW, editor. Explanatory data analysis. Reading (MA): Addison-Wesley; 1977. p. 39-43.
46. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, et al. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997;11:1256-65.